T-cell lymphoma

[Modern Pathology] Ten patients had a history of B cell malignancies, one each of myeloid neoplasm, breast or prostate cancer, and four others had underlying immune disorders. Most patients died, mostly of disease, with a median overall survival of 12.7 months.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated that proportional flux in the levels of aryl hydrocarbon receptor (AhR) nuclear translocator isoforms 1 and 3 modulated AhR signaling in terms of amplitude and expression of distinct gene programs.

[Rafael Pharmaceuticals, Inc. (Globe Newswire, Inc.)] Rafael Pharmaceuticals, Inc. announced the completion of the first cohort of dose escalation with no DLT in the APOLLO 613 Phase I/II clinical trial of devimistat in combination with hydroxychloroquine in patients with relapsed clear cell sarcoma.

[Science Translational Medicine] Researchers found that the cytokine oncostatin M was highly up-regulated in psoriasis, atopic dermatitis, and cutaneous T cell lymphoma, diseases associated with chronic itch.

[Critical Reviews in Oncology Hematology] Investigators review CD200 expression and its role in the immune evasion of non-B cell hematopoietic neoplasms and conclude that CD200 appears to be involved in the immune evasion of malignant cells, which could affect the survival of patients.

[Blood Advances] Researchers showed that tolinapant acted as an efficacious immunomodulatory molecule capable of inducing complete tumor regression in a syngeneic model of T cell lymphoma exclusively in the presence of an intact immune system.